Transaction DateRecipientSharesTypePriceValue
22nd September 2020Advisors Llc Perceptive1,644,785Conversion of derivative$0.00
22nd September 2020Advisors Llc Perceptive1,058,824Open or private purchase$17.00$18,000,008.00
15th September 2020Advisors Llc Perceptive2,911,764Open or private purchase$4.25$12,374,997.00
14th September 2020Advisors Llc Perceptive400,000Open or private purchase$40.00$16,000,000.00
14th September 2020Advisors Llc Perceptive1,800,000Open or private purchase$11.00$19,800,000.00
10th September 2020Advisors Llc Perceptive200,000Open or private purchase$11.24$2,248,000.00
16th July 2020Richard Scott Struthers17,500Open or private sale$14.46$253,107.75
15th July 2020Richard Scott Struthers17,500Open or private sale$15.30$267,722.00
9th July 2020Advisors Llc Perceptive3,200,000Open or private purchase$4.25$13,600,000.00
6th July 2020Matthew K Fust6,181Exercise of derivative$21.00$129,801.00
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen Betz in 2008.

Ticker: CRNX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1658247
Employees: 68
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags